Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Long-Term Debt Repayments (2022)

Orchestra BioMed Holdings (OBIO) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $5.4 million as the latest value for Q2 2022.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $5.4 million in Q2 2022 year-over-year; TTM through Dec 2022 was $6.4 million, a N/A change, with the full-year FY2023 number at $10.8 million, up 68.31% from a year prior.
  • Long-Term Debt Repayments was $5.4 million for Q2 2022 at Orchestra BioMed Holdings, up from $1.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $5.4 million in Q2 2022 to a low of $1.0 million in Q1 2022.